Frequently reported ( in > 10 % of patients ) grade 3-4 adverse events with PAD induction , salvage ASCT , and cyclophosphamide were : neutropenia ( 125 [ 43 % ] of 293 patients after PAD , and 63 [ 76 % ] of 83 patients in the salvage ASCT group vs 11 [ 13 % ] of 84 patients in the cyclophosphamide group ) , thrombocytopenia ( 150 [ 51 % ] after PAD , and 60 [ 72 % ] vs four [ 5 % ] , respectively ) , and peripheral neuropathy ( 35 [ 12 % ] after PAD , and none vs none , respectively ) .